RE:RE:RE:RE:RE:RUMBLE and CASHAgain, I do not believe the company needs the cash, but will welcome it, given the rapid expansion, as has been noted.
I also think Rumble should be given a break. The decision to accelerate warrants was a good one, and he could not wait longer than 5 days once the 10 days closing over $2.00 had occurred as per the warrant agreement, (Warrant Indenture Providing for the Issue of Warrants Dated as of March 5, 2015). I know some have wondered about the timing of the acceleration; but, just FYI, Rumble was obliged to make a decision to force accelerated expiry in the warrant agreement: (Definitions 1.1) “Time of Expiry” means March 5, 2017, subject however to an accelerated expiry of the Warrants if, at any time after September 30, 2015, the closing trade price of the Common Shares on the TSX is equal or superior to $2.00 for any 10 consecutive Trading Days, in which event the Corporation may, within five days after such event, give the Warrantholders and the Warrant Agent a written notice that the Warrants will expire at 5:00 p.m. (Montral Time) on the 30th day from the receipt of such notice.'
Most of the warrants will be exercised if only because they are held by institutions and are an opportunity to take a larger position at fire sale valuations.
Unfortunately, for existing shareholders, I still think Getinge would be foolish to wait much longer to take TSO3 out given the impending and game changing news that will follow in coming months, including 1) FDA extended claims approval is given, 2) FDA gives public recognition in the US that the VP4 is the ONLY low temp sterilizer that can sterilize the Olympus duodenoscope, or 3) FDA creates a time line for general implementation by all health care providers of scope sterilization across the board. Each and all of these news items will put the share price through the roof, and, given orders already are beyond previous expectations, the new management at Getinge knows this better than anyone. TSO3 might be able to handle production of 200 units in 2016, but, as orders grow well beyond this by early or mid-year, TSO3 will have to enlist a secondary manufactuing source, i.e., Getinge, to meet the market demand and reduce back-orders. My understanding is that Getinge does have spare manufacturing capacity both in US as well as in the EU. And, then, why would Getinge see themselves not only doing all of the sales and field work, but making the units over the 200-250 threshold, (+250-500 units per year once this gets going on all cylinders), and not just own the company and make all of the money to be had here? $4.50/share US is a minimum. :)
Great buy, again, today, btw. Don't sweat the weak hands: take advantage of their gifts.
WKH